47 /100
MEDIUM RISK
Score updated May 30, 2026

ADCT — ADC Therapeutics SA Dilution Risk Tracker

Track ADCT dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track ADCT — Get alerts when the score changes →

📊 Score Breakdown

📋 Offering Ability
60
💰 Cash Runway
0
📊 Float Risk
27
⚠️ Warrant Exposure
70
🔄Convertible Debt

🌦️ Dilution Forecast

🌥️
Advisory
Moderate dilution signals present
39%
📜 Warrant Exercise 40%
• Significant warrants: 22% of shares outstanding
• Elevated warrant risk score (70/100)
📉 Score Deterioration 40%
• Score rose 27 points recently (worsening)
💰 Capital Raise 38%
• Active shelf registration ($38M, 9% of market cap)
• Active ATM program with $38M remaining capacity
🔔 Track ADCT — Get forecast alerts →

💹 Market Data

Market Cap$432.45M
Shares Outstanding127.19M
Float100.41M
Cash$231.01M
Debt$436.26M
Short InterestN/A

🏛 Institutional Holdings

QoQ: ↑ 22.8% shares (2025Q4 vs prior)
113 institutional holders · 85.13M shares
#1 Redmile Group, LLC 15.67M shares
#2 TCG Crossover Management, LLC 11.39M shares
#3 Prosight Management, LP 8.48M shares
+ 17 more holders Sign up free to view →

📉 Short Interest

Short Interest5.75M
Days to Cover4.0
% of Float5.7%
FINRA data as of May 15, 2026

📁 Recent SEC Activity

xbrl XBRL WARRANT Mar 31, 2026
xbrl XBRL CONVERTIBLE Dec 31, 2022
424B3 ATM Apr 15, 2026
4 INSIDER TRANSACTION Apr 02, 2026
EFFECT EFFECT Mar 16, 2026
Full SEC filing analysis available with free account

📰 Recent News

No recent news
Track ADCT Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking ADCT — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required
🔬 More Research for ADCT
📊 ADCT FDA Catalyst Timeline & Biotech Grade — BiotechSigns 📡 ADCT Signal Convergence & Dark Pool Activity — StonkWhisper

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.